A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment
Clinical trial NCT01287117 · COMPLETED
Trial details
- NCT number
- NCT01287117
- Sponsor
- Genentech, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2011-02-01
- Primary completion
- 2012-10-01
- Enrollment
- 319
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.